Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GeneDx Holdings Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while GeneDx Holdings Corp trades at $64.93 (market cap $1.95B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | WGS | |
|---|---|---|
Market Cap | $39.89B | $1.95B |
Sector | Health | Technology |
52-Week High | $491.22 | $167.51 |
52-Week Low | $278.09 | $34.51 |
Enterprise Value | $38.15B | $1.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GeneDx Holdings (WGS) trades at $65.64, down 5.4% over 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $427.54 million in 2025 but a net loss of $21.02 million, with profitability metrics like ROE at -30.42% indicating financial strain. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading statements related to the Fabric Genomics acquisition.
While analyst consensus remains strongly bullish with a $75.40 price target, the stock faces significant risks from ongoing litigation and persistent losses. Investment appeal hinges on the company's ability to improve margins and navigate legal challenges, but current fundamentals suggest caution despite optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
